To further evaluate the clinical significance of TIAM1 on resistance to chemotherapeutic agents, we assessed the expression of TIAM1 in another, in-house, independent patient cohort of 72 metastatic CRC patients who underwent primary site resection followed by chemotherapy enrolled at the Kumamoto University (Kumamoto cohort). The gene discussed is TIAM1; the disease is colorectal carcinoma.